Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Bioshares 2024 Conference
22 slides from Island Pharmaceuticals's conference presentation, Jul 10, 2024
Slide 1: Island Pharmaceuticals presentation for Bioshares 2024 Conference
10 July 2024 ASX Announcement Island Pharmaceuticals presentation for Bioshares 2024 Conference MELBOURNE Australia, 10 July 2024: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to provide a copy of the presentation that will be
Slide 2: About Island Pharmaceuticals
About Island Pharmaceuticals Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well- established safety profile, being repurposed for the prevention and treatment of den
Slide 3: Addressing Urgent Viral Disease and Medical Countermeasures Threats
For personal use only ADDRESSING URGENT VIRAL DISEASE AND MEDICAL COUNTERMEASURES THREATS DR PAUL MACLEMAN, EXECUTIVE CHAIR (ASX: ILA) BIOSHARES CONFERENCE | JULY 2024 ISLAND PHARMACEUTICALS 1 JULY 2024
Slide 4: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Island Pharmaceuticals Limited (ABN 641 183 842) (Company or Future performance Island Pharmaceuticals). This presentation contains certain "forward-looking statements". The words "expect", "anticipate", Not an offer or financia
Slide 5: Addressing Urgent Viral Disease and Medical Countermeasures Threats: Assets
For personal use only ADDRESSING URGENT VIRAL DISEASE AND AND MEDICAL COUNTERMEASURES THREATS ASSETS Known small molecules with clinical history Mid/late stage clinical or other abbreviated routes Open USFDA INDs Validated US Govt/military funding support Priority Review Voucher eligible RAPID PATHS
Slide 6: Strategic Checklist
STRATEGIC CHECKLIST For personal use only Clinical history Small molecule Proven preclinical anti-viral activity Eligible for Priority Review Vouchers National and military preparedness need Probable/confirmed non-dilutive funding to support: military, civilian, NGO Fit for our managem
Slide 7: Strategic Connectivity Between Assets: ISLA101 and Galidesivir
STRATEGIC CONNECTIVITY BETWEEN ASSETS ISLA101 (FENRETINIDE) AND GALIDESIVIR For personal use only Both assets are: • Phase II or later • Have open Investigational New Drug applications with FDA • Antivirals, therefore fast to develop and potential for early licensing if sought • Supported by governm
Slide 8: About ISLA-101
For personal use only About ISLA-101 ISLAND PHARMACEUTICALS 6 JULY 2024
Slide 9: Half of the world's population at risk of dengue
For personal use only “About half of the world's population is now at risk of dengue with an estimated 100–400 million infections occurring each year” World Health Organisation, 30 May 2024 ISLAND PHARMACEUTICALS 7 JULY 2024
Slide 10: Targeting Known or Re-purposable Drugs with Reduced Time to Market: ISLA-101
TARGETING KNOWN OR RE-PURPOSABLE DRUGS WITH REDUCED TIME TO MARKET For personal use only ISLA-101 – dengue, Zika, Yellow Fever, Chikungunya, other arboviruses • 45+ human trials of ISLA-101 completed in other indications • Island’s recent SAD study reinforced safety and established the effective hum
Slide 11: Dengue Is Close to Home
DENGUE IS CLOSE TO HOME For personal use only Source 1 Source 2 Source 3 Source 4 (Described as potential super-spreader event) Article sources: 1. https://www.news.com.au/travel/travel-updates/travel-stories/deadly-viral-infection-doubles-in-popular-tourists-spots- for-aussies/news-story/fc32fa4fc3
Slide 12: Dengue in 2050 – A Global Disease
DENGUE IN 2050 – A GLOBAL DISEASE WHO prediction based on projections of future temperatures, rainfall, and For personal use only mosquito populations Europe USA Australia NASA Earth Observatory map by Lauren Dauphin based on data from Janey Messina, University of Oxford - https://earthobservatory.n
Slide 13: US Army CRADA Provides Control Group for Phase II Study
US ARMY CRADA PROVIDES CONTROL GROUP FOR PHASE II STUDY (AND SUBSTANTIAL % OF PHASE II TRIAL COSTS) For personal use only P1 challenge study conducted by Walter Reed Army Institute of Research and SUNY is ILA’s P2 study control data, and enables unprecedented ability to monitor dengue symptoms, incl
Slide 14: Targeting Known or Re-purposable Drugs: Galidesivir
TARGETING KNOWN OR RE-PURPOSABLE DRUGS WITH REDUCED TIME TO MARKET For personal use only GALIDESIVIR – Ebola, Marburg, Zika & and most other RNA viruses • 12 month, non-binding term sheet signed 3 July 2024 (AU) • Phase I human safety data • Proven protective efficacy in a number of lethal animal mo
Slide 15: Commercial Opportunities
COMMERCIAL OPPORTUNITIES BOTH candidates have prophylactic and therapeutic potential For personal use only Travelers Military National Outbreaks Malaria is also a mosquito Relationship with US Army in Millions of patients in Latin borne disease and therefore a place (CRADA, ISLA101). Will America &
Slide 16: Corporate Snapshot
CORPORATE SNAPSHOT Key data Recent ILA trading history For personal use only Share price (AUD1) $0.066 Market cap1 $8.37m Shares on issue1 126,767,093 Listed Options2 32,506,360 Cash3 $1.6m Board of Directors Substantial shareholders Ownership breakdown Dr Paul MacLeman, Executive Chairman Sharehold
Slide 17: Upcoming Milestones
UPCOMING MILESTONES** For personal use only H1 FY 2024 (Jul – Dec 2023) H2 FY 2024 (Jan – Jun 2024) H1 FY 2025 (Jul – Dec 2024) H2 FY 2025 (Jan – Jun 2025) • Key US and Australian • Dose final Single • Obtain ethics • Data readout from patents granted for ISLA- Ascending Dose approval for Phase 2 Ph
Slide 18: Island Pharmaceuticals
For personal use only Island Pharmaceuticals (ASX: ILA) islandpharmaceuticals.com @IslandPharma Island Pharmaceuticals pmacleman@islandpharmaceuticals.com +61 419 401 445 ISLAND PHARMACEUTICALS 16 JULY 2024
Slide 19: Scientific Advisory Board
SCIENTIFIC ADVISORY BOARD For personal use only Dr Leigh Farrell Prof Stephen Thomas MD Dr Amy Patick Leigh has over 30 years’ experience in the US WRAIR – SUNY Upstate BMS – Mayo Clinic biotechnology and pharmaceutical industry and is Professor Stephen Thomas, MD has an international Amy Patick is
Slide 20: ISLA-101 Prevents Viral Replication
ISLA-101 PREVENTS VIRAL REPLICATION For personal use only Mechanism of action (how it works) ISLA-101 reduces viral load1 ISLA-101 inhibits propagation of flaviviruses Above: dose response showing ISLA-101’s ability to protect against dengue infection • To replicate, the virus needs to hijack the nu
Slide 21: Galidesivir Prevents Viral Replication
GALIDESIVIR PREVENTS VIRAL REPLICATION For personal use only Galidesivir inhibits propagation of RNA viruses • RNA-dependent RNA polymerase (RdRp) is crucial in viral replication and transcription • Catalyses viral RNA synthesis and is the therapeutic target of Galidesivir https://link.springer.com/
Slide 22: Players in the Medical Countermeasures Space
PLAYERS IN THE MEDICAL COUNTERMEASURES SPACE For personal use only Programs backed by BARDA and/or NIAID • BioFactura • BioFire Defense • Certara • Emergent BioSolutions • Evotec SE • IDbyDNA (DIGET program) • Juxtopia • DARPA Panacea Program • ARMR • JnJ Blue Knight Consortium https://globalbiodefe